By Benjamin Chiou
Date: Tuesday 22 Jul 2025
(Sharecast News) - French pharma giant Sanofi announced on Tuesday that it is to purchase London-based respiratory virus vaccine developer Vicebio for up to $1.6bn.
The deal, which adds an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to Sanofi's pipeline, is said to complement its...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news